Global Liver Cancer Drugs Market to Reach $9.3 Billion by 2030
The global market for Liver Cancer Drugs estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$9.3 Billion by 2030, growing at a CAGR of 18.6% over the analysis period 2022-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is projected to record a 18.6% CAGR and reach US$5.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chemotherapy segment is readjusted to a revised 16.4% CAGR for the next 8-year period.The U.S. Market is Estimated at $647.3 Million, While China is Forecast to Grow at 24.6% CAGR
The Liver Cancer Drugs market in the U.S. is estimated at US$647.3 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 24.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.8% and 16% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2030.Select Competitors (Total 52 Featured) -
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Exelixis, Inc.
- Merck & Co., Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Liver Cancer Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Cancer Evolves Into the Global Epidemic
- COVID-19 Extends a Major Setback to the World’s Battle Against Cancer
- Liver Cancer: Disease Causes, Risks, Types, Symptoms, Diagnosis & Survival
3. MARKET TRENDS & DRIVERS
- Targeted Therapies Grow in Popularity for Treating Liver Cancer
- Rising Alcoholism & Increased Alcohol Abuse Amid the Pandemic Push Up the Risk of Liver Cancer Incidence
- Global Number of People With Alcohol Abuse Disorders
- What Are the Approved Drugs for Liver Cancer?
- Advancements in the Field of Genomics Brings Hope for the Development of More Potent Cancer Drugs
- New Breakthroughs in Liver Cancer Research Offers Hope
- Artificial Intelligence Emerges to Revolutionize Liver Cancer Diagnoses
- Men More at Risk of Developing Liver Cancer Than Women. Here’s Why
- Global Number of New Cancer Cases in the Male Population by Cancer Type for the Year 2020
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Liver Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 3: World 18-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Targeted Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 6: World 18-Year Perspective for Targeted Drug Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 9: World 18-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 12: World 18-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 15: World 18-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 18: World 18-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 21: World 18-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 22: World Liver Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
UNITED STATES
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 23: USA Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 24: USA Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 25: USA 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 26: USA Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 28: USA 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
CANADA
- Table 29: Canada Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: Canada Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 31: Canada 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 32: Canada Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Canada Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 34: Canada 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
JAPAN
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 35: Japan Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Japan Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 37: Japan 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 38: Japan Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Japan Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 40: Japan 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
CHINA
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 41: China Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: China Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 43: China 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 44: China Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: China Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 46: China 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
EUROPE
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 47: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 48: Europe Historic Review for Liver Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 49: Europe 18-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 52: Europe 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 55: Europe 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
FRANCE
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 56: France Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: France Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 58: France 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 59: France Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: France Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 61: France 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
GERMANY
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 62: Germany Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Germany Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 64: Germany 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 65: Germany Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: Germany Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 67: Germany 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
ITALY
- Table 68: Italy Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Italy Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 70: Italy 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 71: Italy Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Italy Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 73: Italy 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
UNITED KINGDOM
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 74: UK Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: UK Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 76: UK 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 77: UK Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: UK Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 79: UK 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
SPAIN
- Table 80: Spain Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Spain Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 82: Spain 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 83: Spain Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Spain Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 85: Spain 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
RUSSIA
- Table 86: Russia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Russia Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 88: Russia 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 89: Russia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Russia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 91: Russia 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
REST OF EUROPE
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 94: Rest of Europe 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of Europe Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 97: Rest of Europe 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
ASIA-PACIFIC
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Liver Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 100: Asia-Pacific 18-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Liver Cancer Drugs by Therapy Type - Targeted Drug Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 103: Asia-Pacific 18-Year Perspective for Liver Cancer Drugs by Therapy Type - Percentage Breakdown of Value Sales for Targeted Drug Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2023 & 2030
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 106: Asia-Pacific 18-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2023 & 2030
AUSTRALIA
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Exelixis, Inc.
- Merck & Co., Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 277 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 2.4 Billion |
Forecasted Market Value ( USD | $ 9.3 Billion |
Compound Annual Growth Rate | 18.4% |
Regions Covered | Global |